400+


Publications

3,000+


Impact factors

2,000+


Clinical Projects

Publication Highlights


  1. Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics. Hepatology. 2021 December 25; 001-13. doi:10.1002/hep.32308
  2. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nature Communications. 2021 November 19; 12, 6770. doi:10.1038/s41467-021-27022-z
  3. Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes. Nature Communications. 2021 November 8; 12, 6454. doi:10.1038/s41467-021-26806-7
  4. Multi-dimensional fragmentomic assay for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma. Journal of Hematology and Oncology. 2021 October 26;14,175. doi:10.1186/s13045-021-01189-w 
  5. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study. PLOS Medicine. 2021 August 31; doi:10.1371/journal.pmed.1003741
  6. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology and Oncology. 2021 May 17; 14, 80. doi:10.1186/s13045-021-01089-z
  7. Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study. Clinical Cancer Research. 2020 Dec 1;26(23):6168-6175. doi: 10.1158/1078-0432.CCR-20-2081.
  8. Widespread and Functional RNA Circularization in Localized Prostate Cancer. Cell. 2019 Feb 7;176(4):831-843.e22. doi: 10.1016/j.cell.2019.01.025.
  9. Distribution of NRG1 Gene Fusions in a Large Population of Chinese Patients with NSCLC. Journal of Thoracic Oncology. 2019 Dec;14(12):e263-e266. doi: 10.1016/j.jtho.2019.07.012.
  10. Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small-Cell Lung Cancer. Clinical Cancer Research. 2019 Aug 15;25(16):5015-5026. doi: 10.1158/1078-0432.CCR-19-0585.
  11. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer. Theranostics. 2019 Jul 28;9(19):5532-5541. doi: 10.7150/thno.34070.
  12. Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA. Cancer Letters. 2020 Mar 1;472:108-118. doi: 10.1016/j.canlet.2019.12.004.
  13. Timing and Origins of Local and Distant Metastases in Lung Cancer. Journal of Thoracic Oncology. 2021 Mar 12. doi:10.1016/j.jtho.2021.02.023
  14. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut. 2019 Jul;68(7):1152-1161. doi: 10.1136/gutjnl-2018-316522.
  15. High prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations. Brain. 2019 Jan 1;142(1):23-34. doi: 10.1093/brain/awy307.
  16. Clinical And Molecular Features Of Acute Promyelocytic Leukemia With Variant Retinoid Acid Receptor Fusions. Haematologica. 2019 May;104(5):e195-e199. doi: 10.3324/haematol.2018.205369.
  17. Investigating novel resistance mechanisms to third generation EGFR TKI osimertinib in non-small cell lung cancer patients using next generation sequencing. Clinical Cancer Research. 2018 Jul 1;24(13):3097-3107. doi: 10.1158/1078-0432.CCR-17-2310.
  18. Circulating Tumor DNA Mutational Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types. Scientific Reports. 2017 Apr 3;7(1):583. doi: 10.1038/s41598-017-00520-1.
  19. The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC. Journal of Thoracic Oncology. 2016 Sep;11(9):1503-10. doi: 10.1016/j.jtho.2016.05.016.